Australia Biopharmaceutical Cro Market Size & Outlook
The biopharmaceutical cro market in Australia is expected to reach a projected revenue of US$ 3,440.9 million by 2033. A compound annual growth rate of 9.1% is expected of Australia biopharmaceutical cro market from 2025 to 2033.
Revenue, 2024 (US$M)
$1,586.4
Forecast, 2033 (US$M)
$3,440.9
CAGR, 2025 - 2033
9.1%
Report Coverage
Australia
Global Market
Related Markets
Australia biopharmaceutical cro market highlights
- The Australia biopharmaceutical cro market generated a revenue of USD 1,586.4 million in 2024 and is expected to reach USD 3,440.9 million by 2033.
- The Australia market is expected to grow at a CAGR of 9.1% from 2025 to 2033.
- In terms of segment, clinical was the largest revenue generating type in 2024.
- Pre-Clinical is the most lucrative type segment registering the fastest growth during the forecast period.
Biopharmaceutical cro market data book summary
| Market revenue in 2024 | USD 1,586.4 million |
| Market revenue in 2033 | USD 3,440.9 million |
| Growth rate | 9.1% (CAGR from 2025 to 2033) |
| Largest segment | Clinical |
| Fastest growing segment | Pre-Clinical |
| Historical data | 2021 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Drug Discovery, Pre-Clinical, Clinical |
Other key industry trends
- In terms of revenue, Australia accounted for 5.6% of the global biopharmaceutical cro market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, China biopharmaceutical cro market is projected to lead the regional market in terms of revenue in 2033.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 9,785.9 million by 2033.
No credit card required*
Publish Date: Oct 14, 2025
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Biopharmaceutical CRO Market Scope
Biopharmaceutical CRO Market segmentation & scope
Others
Others
Others
Biopharmaceutical CRO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Lonza Group Ltd | View profile | 18,000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | www.lonza.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Charles River Laboratories International Inc | View profile | 21,400 | 251 Ballardvale Street, Wilmington, MA, United States, 01887 | www.criver.com |
| Icon PLC | View profile | 41,150 | South County Business Park, Leopardstown, Dublin, Ireland, D18 X5R3 | www.iconplc.com |
| Catalent Inc | View profile | 17,219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | www.catalent.com |
| PAREXEL | View profile | 10001+ | Waltham, Massachusetts, United States, North America | www.parexel.com |
| Syneos Health | View profile | 1001-5000 | Morrisville, North Carolina, United States, North America | www.syneoshealth.com/ |
| Worldwide Clinical Trials | View profile | 1001-5000 | Morrisville, North Carolina, United States, North America | www.worldwide.com |
| IQVIA | View profile | 10001+ | Danbury, Connecticut, United States, North America | www.iqvia.com |
| Fortrea Holdings Inc | View profile | 16,000 | 8 Moore Drive, Durham, NC, United States, 27709 | www.fortrea.com |
Australia Biopharmaceutical CRO Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Biopharmaceutical CRO Market Outlook will help companies and investors design strategic landscapes.
Clinical was the largest segment with a revenue share of 81.37% in 2024.
Horizon Databook has segmented the Australia biopharmaceutical cro market based on drug discovery, pre-clinical, clinical covering the revenue growth of each sub-segment from 2021 to 2033.
- Australia Biopharmaceutical Cro Market Type Outlook (Revenue, USD Million , 2021-2033)
- Drug Discovery
- Pre-Clinical
- Clinical
- Australia Biopharmaceutical Cro Market Product Outlook (Revenue, USD Million , 2021-2033)
- Monoclonal antibodies (mAbs)
- Recombinant proteins & enzymes
- Vaccines
- Cell & Gene Therapies
- Nucleic acid Therapeutics
- Others
- Australia Biopharmaceutical Cro Market Service Outlook (Revenue, USD Million , 2021-2033)
- Project Management/Clinical Supply Management
- Data Management
- Regulatory/Medical Affairs
- Medical Writing
- Clinical Monitoring
- Quality Management/ Assurance
- Bio-statistics
- Investigator Payments
- Laboratory
- Patient And Site Recruitment
- Technology
- Others
- Australia Biopharmaceutical Cro Market Therapeutic Area Outlook (Revenue, USD Million , 2021-2033)
- Oncology
- CNS Disorders
- Infectious Diseases
- Immunological Disorders
- Cardiovascular Disease
- Respiratory Diseases
- Diabetes
- Ophthalmology
- Pain Management
- Others
- Australia Biopharmaceutical Cro Market End Use Outlook (Revenue, USD Million , 2021-2033)
- Large Pharmaceutical & Biotechnology companies
- Small & Mid-Size Sponsors
- Academic & Government research
Reasons to subscribe to Biopharmaceutical CRO Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Biopharmaceutical CRO Market Outlook databook
- Our clientele includes a mix of Biopharmaceutical CRO Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia Biopharmaceutical CRO Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Australia Biopharmaceutical CRO Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Australia Biopharmaceutical Cro Market, 2021-2033 (US$M)
Australia biopharmaceutical cro market statistics, by type, 2021-2033 (US$M)
